United Community Banks (UCB)
(Delayed Data from NYSE)
$28.62 USD
0.00 (0.00%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $28.61 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
UCB 28.62 0.00(0.00%)
Will UCB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for UCB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UCB
Northrim Bancorp (NRIM) Hikes Quarterly Cash Dividend by 1.6%
Stock Yards Bancorp (SYBT) Hikes Quarterly Cash Dividend by 3.3%
UCB: What are Zacks experts saying now?
Zacks Private Portfolio Services
United Community (UCB) Hikes Dividend, Amends Repurchase Plan
Other News for UCB
United Community Banks, Inc. Announces Date for Third Quarter 2024 Earnings Release and Conference Call
UCB Announces Late-Breaking Two-Year Data for BIMZELX? (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
UCB Presents New 4-year Data for BIMZELX? (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
UCB Announces U.S. FDA Approvals for BIMZELX? (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis